Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step-up” and “top-down” approaches, and has become a cornerstone of IBD management. However, in a proportion of patients the eff...

Full description

Bibliographic Details
Main Authors: Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Medicine
Subjects:
anti-TNF
loss of response
primary non-response
switch out of class
switch within class
therapeutic drug monitoring
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.897936/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.897936/full

Similar Items